Aldeyra Therapeutics Inc (NASDAQ:ALDX) Director C. Boyd Clarke purchased 12,500 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $8.00 per share, with a total value of $100,000.00. Following the acquisition, the director now directly owns 12,500 shares in the company, valued at approximately $100,000. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -8.31% in last session and finished the day at $6.73. Traded volume was 29,866.00million shares in the last session and the average volume of the stock remained 53.93K shares. Aldeyra Therapeutics Inc (NASDAQ:ALDX) insider ownership is 1.30%.
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, on 15 May 2014 announced that its management will present a corporate overview at the 15th BioEquity Europe Conference, May 21-22, 2014, to be held at the Hilton Amsterdam Hotel, Amsterdam, the Netherlands, as well as at Jefferies 2014 Global Healthcare Conference, June 2-5, 2014, to be held at the Grand Hyatt New York, New York City, NY, USA. Uniqure NV (NASDAQ:QURE) dropped -7.20 percent to $8.63 Wednesday on volume of 46,857.00million shares. The intra-day range of the stock was $8.62 to $9.77. Uniqure NV (NASDAQ:QURE) has a market capitalization of $151.84million.
Regulus Therapeutics Inc (NASDAQ:RGLS) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday, AmericanBankingNews.com reports. They currently have a $6.30 price target on the stock. Zacks‘s price target indicates a potential downside of 5.83% from the company’s current price. Regulus Therapeutics Inc (NASDAQ:RGLS)’s stock on May 21, 2014 reported a decrease of -5.53% to the closing price of $6.32. Its fifty two weeks range is $5.40 -$12.89. The total market capitalization recorded $273.95million. The overall volume in the last trading session was 54,358.00million shares. In its share capital, RGLS has 43.35million outstanding shares.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) announced on 16 May 2014 the completion of a series of transactions with the Company’s largest shareholder, Dr. Mervyn Jacobson (collectively, the “Jacobson Entities”). This arrangement commenced on December 18, 2013 resulting in the disposal of 105,937,500 shares in the Company including 30,000,000 Shares which were transferred (by a special crossing) with parties unrelated arrangements outlined below. As a result, Dr. Jacobson’s interest in the issued capital of the Company was reduced from 23.83% to 5.33%. This assumed no other share transactions in the interim. On Wednesday, shares of Genetic Technologies Limited (ADR) (NASDAQ:GENE) dropped -6.36% to close the day at $1.03. Company return on investment (ROI) is -165.40% and its monthly performance is recorded as -27.97%. Genetic Technologies Limited (ADR) (NASDAQ:GENE) quarterly revenue growth is -40.80%.